Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>AI-Driven Drugmaker INSILICO's IPO Starts Tdy; Eli Lilly/ TENCENT/ Temasek Among Cornerstone Investors
Recommend 10 Positive 19 Negative 5 |
||||
|
||||
|
INSILICO (03696.HK), an AI-driven drug discovery and development company, has announced details of its IPO in Hong Kong. The drugmaker offers 94.6905 million shares globally, with the Hong Kong public offering accounting for 10% (9.4695 million shares) and the international offering accounting for 90% (85.221 million shares). The offer price is set at HKD24.05 per share, aiming to raise up to around HKD2.277 billion. The entry fee for a board lot of 500 shares will be around HKD12,146.27. The IPO period starts today (18th) and ends next Tuesday (23rd), with the listing expected on December 30. INSILICO has introduced several well-known companies and institutions as cornerstone investors for this IPO, including Eli Lilly and Company (LLY.US), TENCENT (00700.HK), Temasek, CPIC (02601.HK), RTW Master Fund, and Exome, collectively subscribing for around USD115 million worth of shares. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
